Although imatinib mesylate (IM) is highly effective at inducing complete cytogenetic remission in patients with chronic myelogenous leukemia (CML), it is known to suppress T-cell proliferation in ...

News & Views Published: July 2008 Imatinib buys time for brain after stroke Peter Rieckmann Nature Medicine 14, 712–713 (2008) Cite this article ...

Background: Primary resistance to IM in advanced GIST pts occurs rarely (<15%), but eventually pts may develop secondary resistance, possibly due to other mutations of KIT, genomic amplification of ...

A new FTC report claims that pharmacy benefit managers generated $7.3bn by marking up specialty generics used to treat diseases like cancer and HIV.

Gene-testing specialist Editas Medicine has halted development of its lead clinical programme for congenital eye disorders after it generated lacklustre results in a phase 1/2 trial. The ...

Background: Malignant mesothelioma is a cancer which is refractory to current treatments. Imatinib mesylate is a selective inhibitor of tyrosine kinases such as bcr-abl, c-Kit, c-Fms and platelet ...

Approximately 50% of people with neurofibromatosis type 1 (NF1), one of the most common monogenetic conditions in humans,1 will develop plexiform neurofibromas (PNF), benign but complex nerve sheath ...